×
About 5,003 results

ALLMedicine™ Medulloblastoma Center

Research & Reviews  1,804 results

Etiology- and region-specific characteristics of transependymal cerebrospinal fluid flow.
https://doi.org/10.3171/2022.7.PEDS2246
Journal of Neurosurgery. Pediatrics; Yang PH, Almgren-Bell A et. al.

Aug 14th, 2022 - Transependymal flow (TEF) of CSF, often delineated as T2-weighted hyperintensity adjacent to the lateral ventricles on MRI, is a known imaging finding, usually in the setting of CSF flow disturbances. Specific radiological features of TEF and thei...

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT05096481

Aug 12th, 2022 - This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-...

Arachnoiditis Imaging
https://emedicine.medscape.com/article/336605-overview

Aug 11th, 2022 - Practice Essentials Arachnoiditis is a broad term denoting inflammation of the meninges and subarachnoid space. It is characterized by thickening of the arachnoid membrane and dura mater adhesions that result in chronic lower back pain. Complicati...

Arachnoiditis Imaging
http://emedicine.medscape.com/article/336605-overview

Aug 11th, 2022 - Practice Essentials Arachnoiditis is a broad term denoting inflammation of the meninges and subarachnoid space. It is characterized by thickening of the arachnoid membrane and dura mater adhesions that result in chronic lower back pain. Complicati...

Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04485416

Aug 11th, 2022 - Eltrombopag is an orally administered, small molecule thrombopoietin receptor (TPO-R) agonist that stimulates platelet production by a mechanism similar, but not identical to endogenous TPO. Eltrombopag interacts with the transmembrane domain of t...

see more →

Guidelines  2 results

SEOM clinical guideline for management of adult medulloblastoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057961
Clinical & Translational Oncology : Official Publication ... Luque R, Benavides M et. al.

Apr 2nd, 2021 - Recent advances in molecular profiling, have reclassified medulloblastoma, an undifferentiated tumor of the posterior fossa, in at least four diseases, each one with differences in prognosis, epidemiology and sensibility to different treatments. T...

SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low an...
https://doi.org/10.1002/pbc.25313
Pediatric Blood & Cancer; Parkes J, Hendricks M et. al.

Nov 25th, 2014 - Effective treatment of children with medulloblastoma requires a functioning multi-disciplinary team with adequate neurosurgical, neuroradiological, pathological, radiotherapy and chemotherapy facilities and personnel. In addition the treating cent...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  130 results

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT05096481

Aug 12th, 2022 - This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-...

Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04485416

Aug 11th, 2022 - Eltrombopag is an orally administered, small molecule thrombopoietin receptor (TPO-R) agonist that stimulates platelet production by a mechanism similar, but not identical to endogenous TPO. Eltrombopag interacts with the transmembrane domain of t...

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT02359565

Aug 9th, 2022 - PRIMARY OBJECTIVES: I. To establish the safety and describe adverse effects associated with administration of the adult recommended dose of pembrolizumab (MK-3475) in each stratum separately. II. To estimate the sustained objective response rate, ...

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT04696029

Aug 4th, 2022 - In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study. Subjects will be evaluated in 3 Cohorts: Cohort 1: Molecular High Risk Medulloblastoma Cohort 2: Molecular Very H...

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT02724579

Aug 1st, 2022 - PRIMARY OBJECTIVE: I. To estimate the progression-free survival (PFS) of children >= 3 years of age with wingless-type MMTV integration site family (WNT)-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gray [G...

see more →

News  49 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

Multiple Lesions With Recurrent Bleeding
https://www.mdedge.com/dermatology/article/249160/nonmelanoma-skin-cancer/multiple-lesions-recurrent-bleeding
Diem-Phuong D. Dao, BS, Kimberly Salkey, MD

Nov 29th, 2021 - The Diagnosis: Nevoid Basal Cell Carcinoma Syndrome Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a rare autosomal-dominant disorder that increases the risk for developing various carcinomas and affects multiple o.

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology
https://www.onclive.com/view/new-astro-president-calls-attention-to-in-person-meetings-remaining-challenges-and-ongoing-research-in-radiation-oncology

Nov 24th, 2021 - Following the period of virtual medical meetings due to the COVID-19 pandemic, the field of radiation oncology is navigating the world of hybrid conferences to continue pushing the paradigm forward, said Jeff M. Michalski, MD, MBA, FASTRO, who add...

Dr. Cohen Addresses the Role of the Hedgehog Pathway
https://www.onclive.com/view/dr-cohen-addresses-the-role-of-the-hedgehog-pathway

Oct 6th, 2021 - Deirdre J. Cohen, MD, Assistant Professor, Department of Medicine, Clinical Cancer Center, NYU Medical Oncology Associates, at the Cancer Institute at NYU Langone Medical Center, discusses the normal role of the hedgehog signaling pathway and pote...

see more →

Patient Education  4 results see all →